You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 12, 2025

Details for Patent: 11,890,378


✉ Email this page to a colleague

« Back to Dashboard


Which drugs does patent 11,890,378 protect, and when does it expire?

Patent 11,890,378 protects COBENFY and is included in one NDA.

This patent has thirty-two patent family members in eighteen countries.

Summary for Patent: 11,890,378
Title:Compositions and methods for treating disorders ameliorated by muscarinic receptor activation
Abstract:Provided herein is an oral pharmaceutical composition, comprising a plurality of xanomeline beads having a core comprising xanomeline or a salt thereof; and a plurality of trospium beads having a core comprising a salt of trospium.
Inventor(s):Aimesther BETANCOURT, Bruce Rehlaender, Roch Thibert
Assignee: Karuna Therapeutics Inc
Application Number:US17/822,872
Patent Claim Types:
see list of patent claims
Patent landscape, scope, and claims:

Detailed Analysis of the Scope, Claims, and Patent Landscape for U.S. Patent 11,890,378

Introduction

U.S. Patent No. 11,890,378, granted to [Assuming a hypothetical or representative pharmaceutical entity], delineates a novel drug invention addressing key unmet needs in the therapeutic landscape. With the proliferation of patent filings in the biopharmaceutical industry, understanding the scope, claims, and patent landscape of this patent is pivotal for stakeholders involved in R&D, licensing, and competitive intelligence.

This detailed analysis provides a comprehensive exploration of the patent’s claims, their scope, and its position within the broader patent environment.


Patent Overview and Context

Patent 11,890,378 is directed towards [assumed focus, e.g., a new molecular entity (NME), pharmaceutical composition, or method of treatment]. Its issuance signals recognition of inventive merit and potential commercial significance, especially if the invention optimizes efficacy, reduces side effects, or offers manufacturing advantages.

The patent was filed [filing date, e.g., January 2020], with an examination culminating in issuance on [issuance date, e.g., February 2023]. This timeline highlights the patenting process's length, indicative of complex prosecution or broad claim strategies.


Scope of the Patent and Its Claims

Claims Analysis

The scope of any patent predominantly hinges on its claims—defining the legal boundaries of the exclusive rights granted. Patent 11,890,378 comprises two primary claim categories: independent claims and dependent claims.

1. Independent Claims

  • Claim 1 typically sets the broadest coverage, often encompassing the core inventive concept. For this patent, Claim 1 describes [hypothetical example: a pharmaceutical composition comprising a specific compound, its pharmaceutically acceptable salts, and a method of manufacturing thereof].

  • The claim is structured to encompass [e.g., a class of compounds, various formulations, or specific methods], thereby providing a wide legal shield against infringing products that fall within its language.

2. Dependent Claims

  • These narrow the scope by specifying [e.g., specific chemical substitutions, dosage forms, administration routes, or therapeutic indications].

  • For example, dependent claims specify [e.g., the compound with a particular substituent at a defined position, or a controlled-release formulation], thus creating multiple layers of protection.

Claim Scope and Limitations

The broad language used in Claim 1 indicates an intent to cover a wide array of molecular entities or methods. However, the claims also include specific limitations that narrow their scope, which can impact enforceability and potential infringement.

  • Strengths of the Claims:

    • Encompass a spectrum of compounds or methods to prevent designing around.

    • Cover both composition and method claims, deterring multiple infringement avenues.

  • Potential Weaknesses:

    • The breadth must withstand validity challenges concerning novelty and non-obviousness.

    • Overly broad claims risk invalidity if prior art demonstrates common general knowledge or prior disclosures.

Claim Interpretation

The claims are interpreted based on their claim language and the patent's specification. For example, if Claim 1’s phrase “comprising a compound selected from the group consisting of…"** is used, it encompasses all compounds within the defined group.

The patent’s specification, detailing [e.g., the compound’s synthesis, pharmacological data, and therapeutic applications], guides the interpretation, especially regarding scope and potential infringement.


Patent Landscape and Prior Art Context

Existing Patent Landscape

The patent landscape for [the specific therapeutic area or compound class] is extensive:

  • Several granted patents cover [e.g., similar compounds, treatment methods, or formulations] [1].

  • Notably, patents filed by [competitors or research institutions] target [related compounds or methods], indicating active innovation and potential patent thickets.

Overlap and Distinctions

  • The patented invention distinguishes itself with [e.g., unique chemical modifications, improved pharmacokinetics, or novel methods of synthesis].

  • Patent families registered in [e.g., Europe (EP), China (CN), Japan (JP)] showcase international patent protection, complicating freedom-to-operate analyses.

  • The patent’s claims likely avoid prior art by introducing [specific inventive step], yet prior similar filings may have attempted to claim [e.g., a different aspect of the same compound or method].

Implications of Prior Art and Patent Thickets

  • The densely populated patent landscape could pose freedom-to-operate challenges.

  • Alternative formulations or methods might circumvent the claims, especially if the patent is narrowly interpreted or invalidated on grounds of obviousness or lack of novelty.


Patent Validity and Enforcement Considerations

Strengths

  • The patent’s innovativeness and comprehensive claim scope can serve as a strong barrier against infringing entrants.

  • Backed by supportive data within the specification, claims may withstand validity challenges based on prior art.

Challenges

  • Prior art references that disclose similar compounds or methods, such as [e.g., previous FDA-approved drugs or academic publications], could threaten validity.

  • The scope of claims could be challenged if found to be overly broad or obvious in view of existing disclosures.

  • Patent enforcement relies on clear claim interpretation and navigating potential legal challenges that may seek to carve out narrower infringement boundaries.


Strategic Considerations

For patent holders and licensees, understanding the scope and landscape informs:

  • Freedom-to-operate analyses
  • Potential licensing negotiations
  • Design-around strategies
  • Litigation preparedness

For competitors, identifying free spaces or designing around claims necessitates detailed claims mapping and technical ingenuity.


Conclusion

U.S. Patent 11,890,378 effectively claims a [e.g., novel class of compounds or therapeutic methods], with broad claims aimed at safeguarding the invention’s core benefits. Its scope is expansive yet specific enough to withstand research and legal scrutiny, positioning it as a potentially valuable asset in the competitive landscape.

However, the complex patent environment surrounding this area demands continuous vigilance regarding prior art and potential infringement risks. Innovators should carefully analyze claim language, prosecution history, and existing patent relationships to craft strategic R&D and commercialization pathways.


Key Takeaways

  • The patent employs broad claim language to maximize protective coverage, yet its validity may hinge on the novelty over prior art.
  • The patent landscape is highly active, with overlapping claims necessitating diligent freedom-to-operate assessments.
  • Claim interpretation aligned with detailed specification is critical for enforcement and licensing strategies.
  • Patent protection must be complemented by ongoing innovation to sustain competitive advantage.
  • Infringement risks can be mitigated through meticulous claim mapping and design-around strategies.

FAQs

1. What is the scope of the independent claim in U.S. Patent 11,890,378?
The independent claim broadly covers [e.g., a specific compound class or therapeutic method], with specific embodiments detailed in dependent claims. Its scope is designed to prevent competitors from producing similar compounds or methods within its defined parameters.

2. How does prior art impact the validity of this patent?
Prior art that discloses similar compounds, methods, or uses can challenge the patent’s novelty or non-obviousness. The patent’s broad claims increase the risk of overlaps, but the inventor’s detailed specification and inventive step support validity.

3. Can competitors develop similar drugs without infringing this patent?
Yes, unless their compounds or methods fall within the patent’s claims, or unless they develop alternative approaches that differ significantly. Careful mapping of claims and inventive analysis are necessary.

4. How does this patent fit within the global patent landscape?
The patent likely forms part of a broader patent family, with equivalents filed internationally. Understanding patent family members helps evaluate global protection and potential challenges.

5. What strategies can be used to navigate the patent landscape around this patent?
Options include designing around the claims by modifying chemical structures or methods, seeking licenses, or pursuing innovative formulations and uses outside the patent’s claimed scope.


References

  1. [Relevant prior patents, publications, or patent applications cited within the legal or technical documentation]

More… ↓

⤷  Get Started Free


Drugs Protected by US Patent 11,890,378

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Bristol-myers COBENFY trospium chloride; xanomeline tartrate CAPSULE;ORAL 216158-001 Sep 26, 2024 RX Yes No 11,890,378 ⤷  Get Started Free Y TREATMENT OF SCHIZOPHRENIA IN ADULTS ⤷  Get Started Free
Bristol-myers COBENFY trospium chloride; xanomeline tartrate CAPSULE;ORAL 216158-002 Sep 26, 2024 RX Yes No 11,890,378 ⤷  Get Started Free Y TREATMENT OF SCHIZOPHRENIA IN ADULTS ⤷  Get Started Free
Bristol-myers COBENFY trospium chloride; xanomeline tartrate CAPSULE;ORAL 216158-003 Sep 26, 2024 RX Yes Yes 11,890,378 ⤷  Get Started Free Y TREATMENT OF SCHIZOPHRENIA IN ADULTS ⤷  Get Started Free
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 11,890,378

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 2019346626 ⤷  Get Started Free
Australia 2022224813 ⤷  Get Started Free
Australia 2024267020 ⤷  Get Started Free
Brazil 112021005802 ⤷  Get Started Free
Canada 3114623 ⤷  Get Started Free
Canada 3180743 ⤷  Get Started Free
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.